A new entry into the hot field of molecular diagnostics has rounded up $49 million in venture capital. Formed following the sale of Austin-based Ambion, Asuragen's first round was led by Telegraph Hill Partners.
"With this level of funding, combined with our expertise in miRNAs and pending patents, we are in a strong position to develop highly effective early cancer detection tools," says CEO Matt Winkler. "In addition to a strong management team from Ambion, I am very excited to have Rollie Carlson join as the president for Asuragen. Rollie, with his wide breadth of diagnostic experience and strong general management record, will lead Asuragen in its goal to be a leading player in oncology molecular diagnostics."
- read the release for more information
ALSO: South San Francisco-based Proteolix raised $45 million in its second round. Much of that money will go to trials of its proteasome inhibitor PR-171. Report